Rapport Therapeutics, Inc. (RAPP) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator being developed for focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), and bipolar mania. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $20,000 | $0 |
| Total Operating Expenses | $44,215 | $27,108 |
| Research & Development | $32,716 | $19,572 |
| Selling, General & Administrative | $11,499 | $7,536 |
| Net Loss | $(19,857) | $(24,063) |
| Net Loss Per Share (Basic & Diluted) | $(0.42) | $(0.68) |
| Cash, Cash Equivalents & Short-Term Investments | $476,782 | $490,539 |
| Accumulated Deficit | $(255,085) | $(147,808) |
Note: Cash, cash equivalents, and short-term investments are derived from the balance sheet (Cash $78,056 + Short-term investments $398,726). Restricted cash of $105 is excluded from this liquidity metric per management discussion.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $20.0 million in collaboration revenue in Q1 2026, compared to zero in Q1 2025. This resulted from a non-refundable upfront payment received under a new license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. for the development and commercialization of RAP-219 in Greater China.
- Expense Growth: Total operating expenses increased by $17.1 million (63%) year-over-year.
- R&D Expenses: Increased by $13.1 million, driven primarily by a $6.8 million increase in clinical trial costs for RAP-219 (Phase 3 FOS start-up, Phase 2 bipolar mania, and LAI formulation IND-enabling activities) and a $1.0 million increase in contract manufacturing costs.
- G&A Expenses: Increased by $4.0 million, largely due to higher personnel costs and professional fees associated with the Tenacia agreement execution.
- Net Loss Improvement: Despite higher operating expenses, the net loss decreased by $4.2 million to $19.9 million, primarily due to the $20.0 million revenue recognition and increased interest income ($4.4 million vs. $3.0 million).
- Liquidity: Cash and short-term investments decreased slightly from $490.5 million to $476.8 million, reflecting operating cash usage partially offset by investment maturities and sales.
Guidance, Outlook, and Risks
- Clinical Progress:
- FOS: Phase 2a proof-of-concept results were positive. The company received FDA feedback supporting advancement into two Phase 3 trials, with initiation expected in Q2 2026.
- Bipolar Mania: Phase 2 proof-of-concept trial is progressing; topline results are now expected in Q4 2026 (accelerated from previous H1 2027 guidance).
- DPNP: The FDA removed a clinical hold on the Diabetic Peripheral Neuropathic Pain IND in December 2025, but the company is deferring investment in this program to prioritize the alpha-6-beta-4 nAChR program.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($476.8 million) are sufficient to fund operations and capital expenditures into the second half of 2029.
- Key Risks:
- Capital Needs: The company expects to continue incurring significant losses and will require additional funding in the future.
- Regulatory Uncertainty: Risks related to FDA approval processes, clinical trial outcomes, and potential delays.
- Third-Party Dependence: Reliance on third parties for clinical trials (e.g., NeuroPace for data collection) and manufacturing.
- Intellectual Property: Dependence on in-licensed IP from Janssen Pharmaceutical NV.
Investor Verification Checklist
- Verify the specific terms and milestone payment structure of the Tenacia Biotechnology license agreement (up to $308 million in contingent milestones).
- Confirm the timeline and enrollment status for the upcoming Phase 3 trials in FOS scheduled to initiate in Q2 2026.
- Monitor the Q4 2026 topline data for the bipolar mania Phase 2 trial, noting the accelerated timeline.
- Review the company's cash burn rate relative to the 2029 liquidity runway estimate, considering potential increases in R&D spend.
- Assess the status of the NeuroPace Master Services Agreement and any potential risks related to third-party data collection for clinical trials.